Umoja wa Ulaya -
Kiaisilandi -
EMA (European Medicines Agency)
pyrukynd
agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
mydrane stungulyf, lausn 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml
laboratoires thea* - lidocainum hýdróklóríð; phenylephrinum hýdróklóríð; tropicamidum inn - stungulyf, lausn - 0,2 mg/ml + 3,1 mg/ml + 10 mg/ml
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
duokopt (joz) augndropar, lausn 20 mg/ml + 5 mg/ml
laboratoires thea s.a.s. - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml + 5 mg/ml
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 50 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 50 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 5 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 5 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 25 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 25 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 200 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 200 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 2 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 2 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
lamictal tuggu-/dreifitafla 100 mg
glaxosmithkline pharma a/s - lamotriginum inn - tuggu-/dreifitafla - 100 mg
Aislandi -
Kiaisilandi -
LYFJASTOFNUN (Icelandic Medicines Agency)
seroxat filmuhúðuð tafla 20 mg
glaxosmithkline pharma a/s - paroxetinum hýdróklóríð - filmuhúðuð tafla - 20 mg